Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”

Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”

Bibliographic Details
Format: Article
Language:English
Published: SAGE Publishing 2024-03-01
Series:Cephalalgia Reports
Online Access:https://doi.org/10.1177/25158163241233831
_version_ 1797263470138228736
collection DOAJ
first_indexed 2024-04-25T00:13:31Z
format Article
id doaj.art-7da8b266efaf4f4ca19d1d7edfb6d75a
institution Directory Open Access Journal
issn 2515-8163
language English
last_indexed 2024-04-25T00:13:31Z
publishDate 2024-03-01
publisher SAGE Publishing
record_format Article
series Cephalalgia Reports
spelling doaj.art-7da8b266efaf4f4ca19d1d7edfb6d75a2024-03-13T07:03:19ZengSAGE PublishingCephalalgia Reports2515-81632024-03-01710.1177/25158163241233831Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”https://doi.org/10.1177/25158163241233831
spellingShingle Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”
Cephalalgia Reports
title Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”
title_full Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”
title_fullStr Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”
title_full_unstemmed Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”
title_short Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”
title_sort corrigendum to eptinezumab administered intravenously subcutaneously or intramuscularly in healthy subjects and or patients with migraine early development studies
url https://doi.org/10.1177/25158163241233831

Similar Items